Septic cardiomyopathy;Septische kardiomyopathie

Intensivmedizin und Notfallmedizin

Volumn 43, Issue 6, 2006, Pages 486-497

  Muller Werdan U ^a   Buerke, M ^a   Christoph, A ^a   Flieger, R R ^a   Heinroth, K ^a   Herklotz, A ^a   Russ M ^a   Schlitt, A ^a   Schmidt, H ^a   Soffker G ^a   Werdan, K ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Autonomic dysfunction; Cardiomyopathy, septic; Sepsis; Septic cardiomyopathy; Septic shock; Shock, septic

Indexed keywords

BACTERIAL TOXIN; CATECHOLAMINE; CYTOKINE; HEART MUSCLE DEPRESSANT FACTOR; INTERLEUKIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

AUTONOMIC DYSFUNCTION; CARDIOMEGALY; CARDIOMYOPATHY; CHEMORECEPTOR REFLEX; DISEASE SEVERITY; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; HEART RATE VARIABILITY; HUMAN; INTENSIVE CARE; ISCHEMIA; PROGNOSIS; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE;

EID: 33748766077     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-006-0738-6     Document Type: Review

References (112)

1. Romberg E (1921) Die septische akute Myokarditis. In: Romberg E (Hrsg) Lehrbuch der Krankheiten des Herzens und der Blutgefäße. Enke-Verlag, Stuttgart, S 494
2. Müller-Hoecker J, Haerty W (1986) Pathomorphological aspects of the hearts in septic patients. In: Schlag G, Redl H (eds) Pathophysiology of Shock, Sepsis, and Organ Failure. Elsevier, Berlin Heidelberg New York Oxford, p 18-54
3. Parrillo JE (1989) The cardiovascular pathophysiology of sepsis. Ann Rev Med 40:469-485
4. Schuster H-P (1989) VI. Schlussfolgerungen. In: Werdan K, Schuster H-P, Schlag G, Spilker G, Neumann R (Hrsg) Sepsis: Toxinwirkung, Herzschädigung, Quantifizierung, supportive Therapie mit Immunglobulinen. Intensivmed 26(Suppl 1):152-153
5. Mueller-Werdan U, Reithmann C, Werdan K (eds) (1996) Cytokines and the heart - Molecular mechanisms of septic cardiomyopathy. Landes Company, Austin, USA/Springer, Heidelberg New York Berlin
6. Müller-Werdan U, Werdan K (1999) Septic cardiomyopathy. Current Opinion in Critical Care 5:415-420
7. Müller-Werdan U, Werdan K (2005) Septischer Kreislaufschock und septische Kardiomyopathie. In: Werdan K, Schuster H-P, Müller-Werdan U (Hrsg) Sepsis und MODS, 4. Auflage. Springer, Heidelberg, S 277-358
8. Müller-Werdan U, Prondzinsky R, Witthaut R, Stache N, Heinroth K, Kuhn C, Schmidt H, Busch I, Werdan K (1997) Das Herz bei Sepsis und MODS. Wien Klin Wochenschr [Suppl I]:3-24
9. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) American College of Chest Physicians/Society of Critical Care Medicine Conference Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
10. Levy M, Fink MP, Marshall JC et al (2003) For the International Sepsis Definitions Conference 2001 SCCM/ESICM/ACCP/ATS/SIS: International Sepsis Definition Conference. Intensive Care Med 29:530-538
11. and Crit Care Med 31:1250-1256
12. Schuster H-P, Müller-Werdan U (2005) Definition und Diagnose von Sepsis und Multiorganversagen. In: Werdan K, Schuster H-P, Müller-Werden U (Hrsg) Sepsis und MODS, 4. Auflage. Springer, Heidelberg, S 3-22
13. Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia Ar, Palazzo M, Werdan K, Le Gall JR, for the European Sepsis Study Group (2005) Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 171:461-468
14. Reith S, Werdan K (2005) Sepsis. In: Madler C, Jauch K-W, Werdan K, Siegrist, Pajonk F-G (Hrsg) Das NAW-Buch - Akutmedizin der ersten 24 Stunden, 3. Auflage. Urban & Fischer Elsevier, München Jena S 671-689
15. Prondzinsky R, Werdan K, Buerke M (2004) Kardiogener Schock: Pathomechanismen, klinischer Verlauf, therapeutische Ansätze und Perspektiven. Internist 45:284-295
16. Rauchhaus M, Müller-Werdan U (2001) Zytokine bei Herzerkrankungen. Internist 42:75-84
17. Müller-Werdan U, Schuster H-P (2005) Abriss der Pathophysiologie als Grundlage der Therapie. In: Werden K, Schuster H-P, Müller-Werden U (Hrsg) Sepsis und MODS, 4. Auflage. Springer, Heidelberg, S 23-61
18. Briassoulis G, Narlioglou M, Zavras N, Hatzis T (2001) Myocardial injury in meningococcus-induced purpura fulminans in children. Intensive Care Med 27:1073-1082
19. Grandel U, Hopf M, Buerke M, Hattar K, Heep M, Fink L, Bohle RM, Morath S, Hartung T, Pulamsetti S, Schermuly RT, Seeger W, Grimminger F, Sibelius U (2005) Mechanism of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation 112:691-698
20. Müller-Werdan U, Pfeifer A, Hübner G, Seliger C, Reithmann C, Rupp H, Werdan K (1997) Partial inhibition of protein synthesis by Pseudomonas exotoxin. A deranges catecholamine sensitivity of cultured rat heart myocytes. J Mol Cell Cardiol 29:799-811
21. Müller-Werdan U, Schumann H, Loppnow H et al (1998) Endotoxin and tumor necrosis factor α exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol 30:1027-1036
22. Singer M, De Santis V, Vitale D, Jeffcoate W (2004) Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 364:545-548
23. Brander L, Weinberger D, Henzen C (2003) Heart and brain: a case of focal myocytolysis in severe pneumococcal meningoencephalitis with review of the contemporary literature. Anaesth Intensive Care 31:202-207
24. Brueckmann M et al (2005) Prognostic value of plasma N-terminal probrain natriuretic peptide in patients with severe sepsis. Circulation 112:527-534
25. Castillo JR, Zagler A, Carillo-Jimenez R, Hennekens CH (2004) Brain natriuretic peptide: a potential marker for mortality in septic shock. Int J Infect Dis 8:271-274
26. Charpentier J, Luyt C-E, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut J-F, Mira J-P, Chiche J-D (2004) Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 32:660-665
27. Guest TM, Ramanathan AV, Tuteur PG, Schechtman KB, Ladenson JH, Jaffe AS (1995) Myocardial injury in critically ill patients - a frequently unrecognized complication. JAMA 273:1945-1949
28. Kuhn C, Mueller-Werdan U, Schmitt DV, Lange H, Pilz G, Kreuzer E, Mohr FW, Zerkowski H-R, Werdan K (2000) Improved outcome of APACHE II score-defined escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared to 1988-1999: the ESSICS-study pilot project. Eur J Cardio-thoracic Surg 17:30-37
29. Maeder M, Ammann P, Kiowski W, Rickli H (2005) B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Failure 7:1164-1167
30. Spies C, Haude V, Fitzner R, Schröder K, Overbeck M, Runkel N, Schaffartzik W (1998) Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 113:1055-1063
31. Flieger RR (2005) Pathophysiologie-orientiertes, Prognose-validiertes und praktikables Monitoring von Patienten mit schwerer Sepsis und septischem Schock - Stellenwert von Score-Systemen, Herz-Kreislaufparametern, Infektions- und Inflammationsmarkern und Markern der autonomen Dysfunktion sowie des Skelettmuskel-Sauerstoffpartialdrucks als Komponenten des erweiterten Monitoring im Vergleich. Dissertationsarbeit, Martin-Luther-Universität, Halle-Wittenberg
32. Gödecke A, Decking UKM, Ding Z, Hirchenhain J, Bidmon H-J, Gödecke S, Schrader J (1998) Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res 82:186-194
33. Kostic MM, Petronijevic MR, Jakovljevic VLJ (1996) Role of nitric oxide (NO) in the regulation of coronary circulation. Physiol Res 45:273-278
34. Cunnion RE, Schaer GL, Parker MM et al (1986) The coronary circulation in human septic shock. Circulation 73:637-644
35. Dhainaut JF, Hughebaert M-F, Monsallier JF et al (1987) Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 75:533-541
36. Pilz G, McGinn P, Boekstegers P, Kääb S, Weidenhöfer S, Werdan K (1994) Pseudomonas sepsis does not cause more severe cardiovascular dysfunction in patients than Non-Pseudomonas sepsis. Circ Shock 42:174-182
37. 2+-current in cardiomyocytes. Am J Physiol 260:H869-H876
38. Hallström S, Bernhart E, Müller U, Fürst W, Vogl C, Koidl B, Werdan K, Schlag G (1994) A cardiodepressant factor (CDF) isolated from hemofiltrates of patients in septic and/or cardiogenic shock blocks calcium inward current in cardiomyocytes. Shock 2[Suppl]:15
39. Hoffmann JN, Werdan K, Hartl WH et al (1999) Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 12:174-180
40. Taiberg L, Wong J, Kumar A (2005) Myocardial depression in sepsis and septic shock. Advances in Sepsis 4/3:82-94
41. Levy RJ, Piel DA, Acton PD, Zhu R, Ferrari VA, Karp JS, Deutschman CS (2005) Evidence of myocardial hibernation in the septic heart. Crit Care Med 33:2752-2756
42. Dhainaut J-F, Pinsky MR, Nouria S, Slomka F, Brunet F (1997) Right ventricular function in human sepsis - a thermodilution study. Chest 112:1043-1049
43. Prondzinsky R, Stache N, Witthaut R, Winkler M, Fraunberger P, Walli AK, Seidel D, Werdan K (1997) Multiorgan-failure (MOF) with and without sepsis: differences in incidence and pattern of detected arrhythmias. Crit Care 1(Suppl 1):P30
44. Schaefer S (2006) Arrhythmien und eingeschränkte Herzfrequenzvariabilität bei Patienten mit Score-quantifizierter Sepsis und Score-quantifiziertem MODS - eine prospektive Studie auf einer internistischen Intensivstation. Dissertationsarbeit, Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg
45. Varriale P, Ramaprasad S (1995) Septic cardiomyopathy as a cause of long QT syndrome. J Electrocardiology 28:327-329
46. Müller-Werdan U, Werdan K (2000) Immune modulation by catecholamines - a potential mechanism of cytokine release in heart failure? Herz 25:271-273
47. Müller-Werdan U, Engelmann H, Werdan K (1998) Cardiodepression by tumor necrosis factor α. Eur Cytokine Netw 9:689-691
48. Müller-Werdan U, Jacoby J, Loppnow H et al (1999) Noradrenaline stimulates cardiomyocytes to produce interleukin-6, indicative of a proinflammatory action, which is suppressed by carvedilol. Eur Heart J 20(Suppl):P1721
49. Schwertz H, Müller-Werdan U, Prondzinsky R, Werdan K, Buerke M (2004) Katecholamine im kardiogenen Schock: hilfreich, nutzlos oder gefährlich? Dtsch Med Wochenschr 129:1925-1930
50. Marshal JC (2000) Complexity, chaos, and incomprehensibility: parsing the biology of critical illness. Crit Care Med 28:2646-2648
51. Schmidt H, Müller-Werden U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K (2005) Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 33:1994-2002
52. Scrogin KE, Hatton DC, Chi Y, Luft FC (1998) Chronic nitric oxide inhibition with L-NAME: effects on autonomic control of the cardiovascular system. Am J Physiol 274:R367-R374
53. Tracey KJ (2002) The inflammatory reflex. Nature 420:853-859
54. Schmidt H, Flieger RR, Hennen R, Tymiec P, Winkler M, Hoyer D, Buerke M, Müller-Werdan U, Werdan K (2005) Reversible autonome Dysfunktion bei einer jungen Patientin mit septischem Multiorgandysfunktionssyndrom. Dtsch Med Wochenschr 130:648-651
55. Schmidt HB, Müller-Werdan U, Saworski J, Werdan K (2000) Can LPS or TNF-α narrow the beating rate variability of contracting cardiomyocytes? Shock 13(Suppl):311
56. Schmidt H, Werdan K, Mueller-Werdan U (2001) Autonomic dysfunction in the ICU patient. Current Opinion in Critical Care 7:314-322
57. Wu AHB (2001) Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med 27:959-961
58. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R, Speichermann N, Verner L, Werdan K (2003) Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 29:1696-1702
59. McLean AS, Huang SJ (2006) Intensive care echocardiography. In: Vincent J-L (ed) 2006 yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg, S 131-141
60. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiß A, Krakover R, Vered Z (2003) The role of cardiac power and systemic vascular resistance in the pathopyhsiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Failure 5:443-451
61. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent J-L, Levy MM; for the Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873
62. Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl JMed 345:1368-1377.
63. Editorial: Evans TW (2001) Hemodynamic and metabolic therapy in critically ill patients (345:1417-1418); Correspondence: 346(2002):1025-1026 & 1377
64. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E (2005) Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 33/10:2194-2201
65. Suzuki T, Morisaki H, Serita R et al (2005) Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 33:2294-2301
66. Buerke M, Werdan K (2006) Beta-Agonisten oder eher Beta-Blocker bei septischer Kardiomyopathie? Intensiv-News 10:24-25
67. Boekstegers P, Weidenhöfer S, Kapsner T, Werdan K (1994) Skeletal muscle partial pressure of oxygen in patients with sepsis. Crit Care Med 22:640-650
68. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360:219-223
69. Brealey D, Karyampudi S, Jaques T, Novelli M, Stidwill R, Taylor V, Smolenski R, Singer M (2004) Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol 286:R491-R497
70. Pathan N, Sandford C, Harding SE, Levin M (2002) Characterization of a myocardial depressant factor in meningococcemia. Crit Care Med 30:2191-2198
71. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, Zetoune FS, Su GL, Arbabi S, Sarma JV, Wang SC, Hemmila MR, Ward PA (2006) An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 203/1:53-61
72. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodelling in rats. Circulation 97:1382-1391
73. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Franco F, Peshock R, Thompson M, Giroir B (1998) Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 97:1375-1381
74. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM (1997) Cardiac-specific overexpression of tumor necrosis factor-α causes lethal myocarditis in transgenic mice. J Card Fail 3:117-124
75. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 81:627-635
76. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE (1996) Tumor necrosis factor α and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183:949-958
77. Loppnow H, Werdan K, Reuter G, Flad H-D (1998) The interleukin-1 and interleukin-1 converting enzyme families in the cardiovascular system. Eur Cytokine Netw 9:675-680
78. Müller-Werdan U, Schumann H, Fuchs R, Reithmann C, Loppnow H, Koch S, Zimny-Arndt U, Chang He, Darmer D, Jungblut P, Stadler J, Holtz J, Werdan K (1997 b) Tumor necrosis factor α (TNFα) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 29:2915-923
79. Nakano M, Knowlton AA, Dibbs Z, Mann DL (1998) Tumor necrosis factor-α confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 97:1392-1400
80. Argenziano M, Dean DA, Moazami N, Goldstein DJ, Rose EA, Spotnitz HM, Burkhoff D, Oz MC, Dickstein ML (1998) Inhaled nitric oxide is not a myocardial depressant in a porcine model of heart failure. J Thorac Cardiovasc Surg 115:700-708
81. Balligand J-L (1998) Molecular mechanisms of action of nitric oxide. In: Vincent J-L (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg New York Berlin, S 107-124
82. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G (1998) Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 32:955-963
83. Fukuchi M, Hussain SNA, Giaid A (1998) Heterogenous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure - their relation to lesion site and β-adrenergic receptor therapy. Circulation 98:132-139
84. Groeneveld ABJ, Hartemink KJ, de Groot MCM, Visser J, Thijs LG (1999) Circulating endothelin and nitrate-nitrite relate to hemodynamic and metabolic variables in human septic shock. Shock 11:160-166
85. Hayward CS, Kalnins WV, Rogers P, Feneley MP, MacDonald PS, Kelly RP (1997) Effect of inhaled nitric oxide on normal human left ventricular function. J Am Coll Cardiol 30:49-56
86. Kelly RA, Balligand J-L, Smith TW (1996) Nitric oxide and cardiac function. Circ Res 79:363-380
87. Paulus WJ (1999) Myocardial inducible nitric oxide synthase and left ventricular performance in the human heart. In: Vincent J-L (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg New York Berlin, S 497-503
88. Thoenes M, Förstermann U, Tracey WR, Bleese NM, Nüssler AK, Scholz H, Stein B (1996) Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol 28:165-169
89. Vandecastelle G, Eschenhagen T, Scholz H, Stein B, Verde I, Fischmeister R (1999) Muscarinic and β-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase. Nature Medicine 5:331-334
90. Oral H, Dorn GW, Mann DL (1997) Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J Biol Chem 272:4836-4842
91. 2) synthesis in rat cardiomyocytes. Naunyn-Schmiedeberg's Arch Pharmacol 349:175-182
92. Gellerich FN, Trumbeckaite S, Hertel K, Zierz S, Müller-Werdan U, Werdan K, Redl H, Schlag G (1999) Impaired energy metabolism in hearts of septic baboons: diminished activities of complex I and complex II of the mitochondrial respiratory chain. Shock 11:336-341
93. Kelm M, Schäfer S, Dahmann R, Dolu B, Perings S, Decking UKM, Schrader J, Strauer B (1997) Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovascular Research 36:185-194
94. Xie Y-W, Kaminski PM, Wolin MS (1998) Inhibition of rat cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrie formation during posthypoxic reoxygenation. Circ Res 82:891-897
95. Zell R, Geck P, Werdan K, Boekstegers P (1997 ) TNF-α and IL-1β inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol Cell Biochem 177:61-67
96. Comstock KL, Krown KA, Page MT, Martin D, Ho P, Pedraza M, Castro EN, Nakajima N, Glembotsik CC, Quintana PJE, Sabbadini RA (1998) LPS-induced TNF-α release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 30:2761-2775
97. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE, Sabbadini RA (1996) Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. J Clin Invest 98:2854-2865
98. Natoli G, Costanzo A, Guido F, Moretti F, Levrero M (1998) Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 56:915-920
99. Singal PK, Khaper N, Palace V, Kumar D (1998) The role of oxidative stress in the genesis of heart disease. Cardiovascular Research 40:426-432
100. Szabo C (1996) The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock 6:79-88
101. Wong SCY, Fukuchi M, Melnyk P, Rodger I, Giaid A (1998) Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 98:100-103
102. Obata T, Sato T, Yamanaka Y, Arita M (1998) NO and cGMP facilitate adenosine production in rat hearts via activation of ecto-5′-nucleotidase. Pflügers Arch - Eur J Physiol 436: 984-990
103. Bernardin G, Strosberg, Bernard A, Mattei M, Marullo S (1998) β-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med 24:1315-1322
104. Boillot A, Massol J, Maupoil V, Grelier R, Capellier G, Berthelot A, Barale F (1996) Alterations of myocardial and vascular adrenergic receptor-mediated responses in Escherichia coli-induced septic shock in the rat. Crit Care Med 24/8:1373-1380
105. De Backer D, Creteur J, Preiser JC et al (2002) Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166:98-104
106. Dhainaut J-F A, Vinsonneau C, Journois D (1999) Hemofiltration and left ventricular function in sepsis: Mechanisms and clinical implications. Crit Care Med 27:473-474
107. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D (1996) Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med 22:1360-1367
108. Avontuur JAM, Boomsma F, van den Meiracker AH, de Jong FH, Bruining HA (1999) Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation 99:271-275
109. Harding SE, Davies CH, Money-Kyrle AM, Poole-Wilson PA (1998) An inhibitor of nitric oxide synthase does not increase contraction or β-adrenoceptor sensitivity of ventricular myocytes from failing human heart. Cardiovascular Research 40:523-529
110. Iwama H, Komatsu T (1998) Effect of an endotoxin-removing column containing immobilized polymyxin B fiber in a patient with septic shock from Gram-positive infection. Acta Anaesthesiol Scand 42:590-593
111. Reinhart K, Meier-Hellmann A, Beale R et al (2004) Open randomized phase II trial of an extra corporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 32:1662-1668
112. Wagner DR, McTiernan C, Sanders VJ, Feldman AM (1998) Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-α in the failing human heart. Circulation 97:521-524